GlassScriptPhysician profile
James Anastasi
NPI 1649280074
$3,572.93
in general payments reported to CMS, 2019-2025
29 companies · $488 in 2025
The $488 reported for 2025 was more than what 78% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $743 · 2020: $462 · 2021: $517 · 2022: $382 · 2023: $447 · 2024: $535 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,469.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,469.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,201.09 | 2019-2025 | Synthroid, Vraylar |
| Amgen INC. | $655.24 | 2019-2025 | Evenity, Prolia |
| Pfizer INC. | $333.86 | 2020-2025 | |
| Astellas Pharma US INC | $167.43 | 2019-2021 | |
| Glaxosmithkline, LLC. | $128.21 | 2019-2025 | Arexvy, Shingrix, Nucala |
| E.R. Squibb & Sons, L.L.C. | $126.69 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $102.01 | 2024-2025 | |
| Lilly USA, LLC | $96.81 | 2023-2025 | Mounjaro, Kisunla, Zepbound |
| Biogen, INC. | $70.68 | 2020-2021 | |
| Exact Sciences Corporation | $61.75 | 2023-2025 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $59.37 | 2022-2023 | |
| Kowa Pharmaceuticals America, INC. | $52.33 | 2019-2022 | |
| Abbott Laboratories | $49.92 | 2021-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.90 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $45.14 | 2019-2025 | Wegovy |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $39.25 | 2023-2024 | Breztri, Farxiga |
| Arbor Pharmaceuticals, INC. | $37.55 | 2019 | |
| Idorsia Pharmaceuticals US INC | $34.16 | 2022-2023 | Quviviq |
| Vertex Pharmaceuticals Incorporated | $33.22 | 2025 | |
| Mannkind Corporation | $32.90 | 2021 | |
| Viiv Healthcare Company | $30.85 | 2024 | Apretude |
| Endo Pharmaceuticals INC. | $24.44 | 2020 | |
| Almatica Pharma LLC | $24.23 | 2024 | Loreev Xr, Teriparatide |
| Sanofi-Aventis U.S. LLC | $21.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $21.54 | 2019 | |
| Eusa Pharma (US) LLC | $21.07 | 2022 | |
| Recordati_rare_diseases_inc. | $21.07 | 2022 | |
| Eisai INC. | $20.47 | 2021 | |
| Ibsa Pharma INC. | $14.19 | 2025 | Tirosint, Licart, Flector |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Anastasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.